Global Bacterial Infectious Diseases Therapeutics Market - 2020-2027
|細菌性感染疾病治療藥的全球市場(2020年∼2027年) Global Bacterial Infectious Diseases Therapeutics Market - 2020-2027|
|出版日期: 2020年11月04日||內容資訊: 英文||
Bacterial infectious diseases are the infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including the rod-shaped (bacilli), spherical (cocci), or helical (spirilla).
Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by the various signs and symptoms including the bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.
The global bacterial infectious diseases therapeutics market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Growing Older Population is Driving the Growth of the Market
The demand of the bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at the high risk of developing the bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.
According to the United Nations (UN) report, the older population of age-group 65 years or above was 703 million worldwide in 2019. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has higher older population in comparision to the Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.
Increasing Antibacterial Resistance is Expected to boost the Development of Therapeutics over the Forecast Period.
There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)'s new Global Antimicrobial Surveillance System (GLASS), the antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 3.4% of new TB cases and 18% of previously treated cases had MDR-TB/ RR-TB in 2018.
Several factors such as misuse and overuse of antibacterials, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in health-care facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is rising spread of multi- and pan-resistant bacteria infection not being treatable by using the existing antibacterials worldwide.
The increasing antibacterial resistance has resulted in rising development of the therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of the several therapeutics being developed. Several companies are developing the therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterials. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in pipeline, only six were classified as innovative.
Rising Organizations & Institutes Intiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth
Several organizations & institutes have raised the intiatives for overcoming the antibacterial resistance. For instance, in October 2015, the World Health Organization (WHO) has launched the Global Antimicrobial Resistance Surveillance System (GLASS) for supporting the global action plan on antimicrobial resistance that aims to support global surveillance and research for strengthening the evidence base on antimicrobial resistance (AMR). World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.
The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.
COVID-19 Impact Analysis
The bacterial infectious diseases therapeutics has witnessed the drastic growth with the increasing number of the people suffering from the COVID-19 as the antibacterials are being used for the treatment of bacterial infections among the patients with COVID-19. Various bacteria species such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumoniae, Enterobacter spp., Escherichia coli, Acinetobacter spp., and Pseudomonas spp are causing the infection among the patients with COVID-19.
According to the Bradley J. Langford et.al., 2020 study published in clinical microbiology & infection (CMI), bacterial co-infection was observed among 3.5% of COVID-19 patients and 14.3% of COVID-19 patients. Approximately, 71.9% of COVID-19 patients received antibiotics for the treatment of bacterial infections. Antibiotics such as azithromycin, ceftriaxone, quercetin, rapamycin, doxycycline, and other antibiotics are mostly recommended among the patients. Azithromycin has demonstrated the anti-inflammatory effects that can be useful for reducing an overactive immune response to COVID-19.
According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, the prevalence of the Rheumatoid Arthritis (RA) was found to be 395.5 per 100,000 in the United States in 2017. Women are two to three times as likely to be affected in comparision to the men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn's Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn's Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.
Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market
By therapeutics, the market is classified as the beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. Beta-lactam segment is anticipated to hold the largest share as it is most most prescribed antibacterials for for the prevention & treatment of the bacterial infection. The beta-lactam acts by inhibiting the ell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. B-Lactam antibiotics is effective against the broad range of clinical indications. Penicillins, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterials with the highest market penetration.
There is increasing research and development activities for the beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).
By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period
The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies is segmented to have the highest market growth due to the high availability of the therapeutics for the treatment of the bacterial infectious diseases in the retail pharmacies & drug stores. There is increase in the number of the retail stores across the globe. According to the cross-sectional survey conducted from the August to October 2014, approximately 93.5% of antibiotics including the amoxicillin and trimethoprim-sulfamethoxazole were prescribed by majority of the registered drug shops.
North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market
North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2019 owing to the increasing prevalence of the bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 9,105 in the United States in 2017. The total number of incidence cases of salmonella and Lyme disease was 54,285 and 42,743 respectively in the United States in 2017. There is growing prevalence of the antibacterial resistant infection. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by the antibiotic-resistant infections in 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.
The United States accounts for the highest market share due to the higher usage of the therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval & launch of the therapeutics for the treatment of bacterial infectious diseases. For instance, in October 2018, Paratek Pharmaceuticals, Inc. had received the approval for the Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). In August 2018, Tetraphase Pharmaceuticals, Inc. had received the approval from the United States Food and Drug Administration (FDA) for the Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.
Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period
Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of the bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities & infrastructure shall have a positive impact on the market.
There is increasing research and development activities for the development of the therapeutics for the treatment of bacterial infectious diseases. There is presence of the several market players developing the therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of the antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.
The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck & Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,
The global bacterial infectious diseases therapeutics market report would provide an access to an approx. 61 market data table, 58 figures and 230 pages.
LIST NOT EXHAUSTIVE